YIRUI Pharma Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Series A2

  • Latest Deal Amount
  • $14.7M

  • Investors
  • 7

YIRUI Pharma General Information

Description

Developer of small molecule innovative targeted drugs designed for the treatment of autoimmune and chronic inflammatory diseases. The company focuses on the research and development of highly selective ion channel inhibitors, including its lead candidate yr001, intended to provide first-line therapeutic solutions for atopic dermatitis, psoriasis, and diabetic complications through both topical and oral administration methods.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 201, Building 2, Pharmaceutical Port
  • Number 291 Fucheng Road, Xiasha Street, Qiantang New District
  • Hangzhou, Zhejiang 310000
  • China
+86 0571
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Room 201, Building 2, Pharmaceutical Port
  • Number 291 Fucheng Road, Xiasha Street, Qiantang New District
  • Hangzhou, Zhejiang 310000
  • China
+86 0571

YIRUI Pharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

YIRUI Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A2) 14-May-2026 $14.7M Completed Generating Revenue
2. Later Stage VC (Series A1) 26-Oct-2023 Completed Generating Revenue
1. Early Stage VC (Series A) 29-Jun-2022 $5.23M $5.23M Completed Generating Revenue
To view YIRUI Pharma’s complete valuation and funding history, request access »

YIRUI Pharma Patents

YIRUI Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026200879-A1 Trpc6 inhibitor and preparation method therefor and use thereof Pending 27-Mar-2025
EP-4834884-A1 Trpv3 inhibitor, and preparation therefor and use thereof Pending 29-Dec-2023
WO-2025139868-A1 Trpv3 inhibitor, and preparation therefor and use thereof Inactive 29-Dec-2023
EP-4538261-A1 N-tetrazolyl aryl urea derivatives, preparation method therefor, and use thereof Pending 07-Jun-2022
EP-4538261-A4 N-tetrazolyl aryl urea derivatives, preparation method therefor, and use thereof Pending 07-Jun-2022 C07D405/12
To view YIRUI Pharma’s complete patent history, request access »

YIRUI Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

YIRUI Pharma Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hangzhou Chaosheng Investment Management Growth/Expansion Minority
Ordos Group Corporation Minority
Hangzhou Shenghui Jingchen Investment Management Growth/Expansion Minority
Hangzhou Tailong Venture Capital Partnership Growth/Expansion Minority
Hangzhou Tigermed Consulting Company Corporation Minority
You’re viewing 5 of 7 investors. Get the full list »

YIRUI Pharma FAQs

  • When was YIRUI Pharma founded?

    YIRUI Pharma was founded in 2018.

  • Where is YIRUI Pharma headquartered?

    YIRUI Pharma is headquartered in Hangzhou, China.

  • What is the size of YIRUI Pharma?

    YIRUI Pharma has 22 total employees.

  • What industry is YIRUI Pharma in?

    YIRUI Pharma’s primary industry is Drug Discovery.

  • Is YIRUI Pharma a private or public company?

    YIRUI Pharma is a Private company.

  • What is YIRUI Pharma’s current revenue?

    The current revenue for YIRUI Pharma is .

  • How much funding has YIRUI Pharma raised over time?

    YIRUI Pharma has raised $19.9M.

  • Who are YIRUI Pharma’s investors?

    Hangzhou Chaosheng Investment Management, Ordos Group, Hangzhou Shenghui Jingchen Investment Management, Hangzhou Tailong Venture Capital Partnership, and Hangzhou Tigermed Consulting Company are 5 of 7 investors who have invested in YIRUI Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process